Alpha Tau Medical Ltd. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
DRTS Nasdaq 3840 www.alphatau.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpha Tau Medical Ltd.

Alpha Tau to Participate in October Investor Conferences - Oct 5th, 2026 7:45 am
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Vistra, Nike to Open Higher - Oct 5th, 2026 4:36 am
Alpha Tau to Participate in September Investor Conferences - Sep 2nd, 2026 6:00 am
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions - Aug 31st, 2026 6:00 am
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness - Aug 28th, 2026 3:30 am
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee - Aug 17th, 2026 6:00 am
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 10th, 2026 2:01 pm
Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo Trial - Aug 1st, 2026 12:16 am
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success - Jul 21st, 2026 6:30 am
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center - Jul 15th, 2026 6:30 am
New Strong Sell Stocks for July 7th - Jul 7th, 2026 6:31 am
New Strong Sell Stocks for July 2nd - Jul 2nd, 2026 1:49 am
Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform - Jun 27th, 2026 1:06 pm
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet - Jun 25th, 2026 9:35 am
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel - Jun 23rd, 2026 6:30 am
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control - Jun 11th, 2026 6:30 am
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing - Jun 3rd, 2026 8:52 am
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients - Jun 3rd, 2026 6:30 am
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - Jun 1st, 2026 7:00 am
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears - May 29th, 2026 7:03 am